Latest Headlines

Latest Headlines

UPDATED: Dx company Alere sells its health services unit for $600M amid continued restructuring

Alere continued down the path of deleveraging and refocusing on its core competency in diagnostics with the sale of its Alere Health unit to Optum, a part of the insurance company UnitedHealth Group for $600 million.

UnitedHealth lobbies for molecular Dx management

With use of molecular diagnostics tests widely expected to skyrocket in the coming decade, UnitedHealth Group is getting increasingly nervous about the trend and looking for ways to manage their use and expense.

UnitedHealth wins access to GSK plaintiff names

A Philadelphia judge has opened the door for UnitedHealth to file subrogation claims against GlaxoSmithKline on behalf of some of its members who may have been injured by the drugmaker's products.

UnitedHealth targets cancer-drug payments

UnitedHealth is ramping up a reimbursement test that could have long-term effects on sales of the most expensive cancer drugs. The insurer will test a payment system that reimburses oncologists for

UnitedHealth to steer patients away from Vytorin, Zetia

More pressure on Merck's cholesterol franchise: UnitedHealth Group is doubling the co-pays on Zetia and Vytorin. Beginning July 1, patients will have to pay $50 to $60 for those cholesterol

FDA to piggyback on insurers' databases

Remember that drug-safety database Congress required the FDA to set up? The idea was for the FDA to actively monitor drugs and possible adverse effects, rather than waiting for doctors and drug

Woodcock: FDA wary of Vytorin debate

Expect the FDA to stay out of the Vytorin fray, at least for now. So Janet Woodcock (

UnitedHealth stands by Vytorin

We didn't have to wait long for a Vytorin decision  from UnitedHealth Group. The largest U.S. insurer says